Proactive Investors
16 Jan 2026, 14:27 UTC · 38w ago
Verdict
Headline takes no side. We score BIVI +0.60 across three claims — strongly bullish.
+0.60strongly bullish
More positive than 79% of ticker scores this week
Scored by the NIS engine · methodology.
What the story claims
3 claims · scored −1 bearish … +1 bullish
BioVie has completed enrollment in its Phase 2 SUNRISE-PD trial testing bezisterim for early Parkinson's disease, with results expected in the first half of 2026.
More positive than 99% of claims this week
The SUNRISE-PD trial is testing whether bezisterim can deliver benefits on its own in early Parkinson's, whereas prior trials only showed symptom improvement when the drug was added to levodopa.
Continue reading
5 related stories
Search tags
More positive than 94% of claims this week
BioVie is also running studies for bezisterim in Long COVID and Alzheimer's disease, with further data expected through 2026.
So whatMultiple ongoing programs across major indications provide pipeline optionality and additional catalysts, broadening the company's potential market footprint.
More positive than 80% of claims this week
Which stocks this story touches
More positive than 79% of ticker scores this week
The company has successfully completed enrollment for a mid-stage trial for Parkinson's disease and is progressing with other studies.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
11h ago
+0.8%
Price agrees with the score
$1.19 vs $1.18 close before publication (Jan 15) · not market-adjusted
BIVI chart →
